Aclaris Therapeutics, Inc. (ACRS) stock
ACRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30138% above fair value
$3.50+0.12 (+3.55%)
Close on Nov 18, 2026Market cap $515.20MP/E –Yield –
Aclaris Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Aclaris Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $8.22M, down 51.0% year over year. For fiscal 2025 it was $7.83M, down 58.2% from the year before. The highest annual figure on record is $31.25M in fiscal 2023.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.83M | -58.2% |
| FY2024 | Dec 31, 2024 | $18.72M | -40.1% |
| FY2023 | Dec 31, 2023 | $31.25M | +5.0% |
| FY2022 | Dec 31, 2022 | $29.75M | +340.1% |
| FY2021 | Dec 31, 2021 | $6.76M | +4.3% |
| FY2020 | Dec 31, 2020 | $6.48M | +53.3% |
| FY2019 | Dec 31, 2019 | $4.23M | -31.3% |
| FY2018 | Dec 31, 2018 | $6.15M | +265.5% |
| FY2017 | Dec 31, 2017 | $1.68M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.63M | -8.3% |
| Q1 FY2026 | Mar 31, 2026 | $2.00M | +37.2% |
| Q4 FY2025 | Dec 31, 2025 | $1.30M | -85.9% |
| Q3 FY2025 | Sep 30, 2025 | $3.30M | -24.1% |
| Q2 FY2025 | Jun 30, 2025 | $1.78M | -35.8% |
| Q1 FY2025 | Mar 31, 2025 | $1.46M | -39.3% |
| Q4 FY2024 | Dec 31, 2024 | $9.21M | -47.6% |
| Q3 FY2024 | Sep 30, 2024 | $4.35M | -53.2% |
| Q2 FY2024 | Jun 30, 2024 | $2.77M | +48.0% |
| Q1 FY2024 | Mar 31, 2024 | $2.40M | -5.1% |
| Q4 FY2023 | Dec 31, 2023 | $17.57M | +126.6% |
| Q3 FY2023 | Sep 30, 2023 | $9.28M | -51.2% |
| Q2 FY2023 | Jun 30, 2023 | $1.87M | +22.3% |
| Q1 FY2023 | Mar 31, 2023 | $2.53M | +74.0% |
| Q4 FY2022 | Dec 31, 2022 | $7.75M | +416.5% |
| Q3 FY2022 | Sep 30, 2022 | $19.02M | +1046.4% |
| Q2 FY2022 | Jun 30, 2022 | $1.53M | -16.2% |
| Q1 FY2022 | Mar 31, 2022 | $1.45M | -18.2% |
| Q4 FY2021 | Dec 31, 2021 | $1.50M | -5.0% |
| Q3 FY2021 | Sep 30, 2021 | $1.66M | +14.5% |
| Q2 FY2021 | Jun 30, 2021 | $1.82M | -10.9% |
| Q1 FY2021 | Mar 31, 2021 | $1.78M | +26.3% |
| Q4 FY2020 | Dec 31, 2020 | $1.58M | +44.3% |
| Q3 FY2020 | Sep 30, 2020 | $1.45M | +47.4% |
| Q2 FY2020 | Jun 30, 2020 | $2.05M | +130.9% |
| Q1 FY2020 | Mar 31, 2020 | $1.41M | +11.4% |
| Q4 FY2019 | Dec 31, 2019 | $1.10M | -70.2% |
| Q3 FY2019 | Sep 30, 2019 | $983.00K | -12.1% |
| Q2 FY2019 | Jun 30, 2019 | $886.00K | -75.9% |
| Q1 FY2019 | Mar 31, 2019 | $1.26M | +13.0% |
| Q4 FY2018 | Dec 31, 2018 | $3.67M | +267.3% |
| Q3 FY2018 | Sep 30, 2018 | $1.12M | +63.5% |
| Q2 FY2018 | Jun 30, 2018 | $3.68M | – |
| Q1 FY2018 | Mar 31, 2018 | $1.12M | – |
| Q4 FY2017 | Dec 31, 2017 | $999.00K | – |
| Q3 FY2017 | Sep 30, 2017 | $684.00K | – |
See a number that looks wrong?